Skip to content
Triangle logo TriangleGet started
← Childhood Non-Hodgkin Lymphoma

NCT01190930 · STUDY IN CONTEXT

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found because this study's registry identifier is printed in an FDA approval notice, an FDA product label or an NCI summary held by this site. The citing document and the exact position of the identifier inside it are recorded. Being cited is not a statement that the study supports this treatment.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated.

Average Risk (AR) B-ALL patients who were randomized and started maintenance

→

primary · POSTED

DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated.

Average Risk (AR) B-ALL patients who were randomized and started maintenance

→

primary · POSTED

DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated.

Source null

→

primary · POSTED

DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated.

Source null

→

primary · POSTED

Percent of B-LLy patients who had adequate/usable samples of samples collected will be reported.

patients who had samples collected near diagnosis

→

primary · POSTED

EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated.

Ineligible patients are excluded

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0007
source section id
NCT01190930-om-0007
source outcome index
7
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional
measure definition
Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
2 Months
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0008
source section id
NCT01190930-om-0008
source outcome index
8
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional
measure definition
Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
1 year
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0009
source section id
NCT01190930-om-0009
source outcome index
9
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional
measure definition
Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
1.7 years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0010
source section id
NCT01190930-om-0010
source outcome index
10
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
measure definition
Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
2.5 years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0011
source section id
NCT01190930-om-0011
source outcome index
11
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional
measure definition
Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Genetic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
3.2 years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR boy patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0012
source section id
NCT01190930-om-0012
source outcome index
12
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical
measure definition
Age and gender standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
2 Months
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0013
source section id
NCT01190930-om-0013
source outcome index
13
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical
measure definition
Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
1 Year
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0014
source section id
NCT01190930-om-0014
source outcome index
14
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical
measure definition
Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
1.7 years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0015
source section id
NCT01190930-om-0015
source outcome index
15
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
measure definition
Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
2.4 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0016
source section id
NCT01190930-om-0016
source outcome index
16
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical
measure definition
Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
3.2 years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR boy patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: School

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0017
source section id
NCT01190930-om-0017
source outcome index
17
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: School
measure definition
Age standardized Quality of life, measured by the school subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
2 Months
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Data are unavailable
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: School

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0018
source section id
NCT01190930-om-0018
source outcome index
18
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: School
measure definition
Age standardized Quality of life, measured by the school subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
1 Year
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Data are unavailable
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: School

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0019
source section id
NCT01190930-om-0019
source outcome index
19
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: School
measure definition
Age standardized Quality of life, measured by the school subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
1.7 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Data are unavailable
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): School

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0020
source section id
NCT01190930-om-0020
source outcome index
20
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): School
measure definition
Age standardized Quality of life, measured by the school subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
2.4 years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Data are unavailable
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in Boy AR Patients Overall at End of Therapy: School

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0021
source section id
NCT01190930-om-0021
source outcome index
21
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in Boy AR Patients Overall at End of Therapy: School
measure definition
Age standardized Quality of life, measured by the school subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
3.2 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Data are unavailable
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Social Functioning

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0022
source section id
NCT01190930-om-0022
source outcome index
22
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Social Functioning
measure definition
Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
2 Months
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Social Functioning

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0023
source section id
NCT01190930-om-0023
source outcome index
23
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Social Functioning
measure definition
Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
1 Year
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Social Functioning

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0024
source section id
NCT01190930-om-0024
source outcome index
24
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Social Functioning
measure definition
Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
1.7 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0025
source section id
NCT01190930-om-0025
source outcome index
25
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
measure definition
Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
2.4 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in Boy AR Patients Overall at End of Therapy: Social Functioning

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0026
source section id
NCT01190930-om-0026
source outcome index
26
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in Boy AR Patients Overall at End of Therapy: Social Functioning
measure definition
Age standardized Quality of life, measured by the Social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
time frame
3.2 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR boy patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Emotional

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0027
source section id
NCT01190930-om-0027
source outcome index
27
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Emotional
measure definition
Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported.
time frame
1.7 years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0028
source section id
NCT01190930-om-0028
source outcome index
28
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
measure definition
Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported.
time frame
2.4 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Emotional

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0029
source section id
NCT01190930-om-0029
source outcome index
29
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Emotional
measure definition
Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported.
time frame
3.2 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR boy patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Physical

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0030
source section id
NCT01190930-om-0030
source outcome index
30
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Physical
measure definition
Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported.
time frame
1.7 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0031
source section id
NCT01190930-om-0031
source outcome index
31
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
measure definition
Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported.
time frame
2.4 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Physical

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0032
source section id
NCT01190930-om-0032
source outcome index
32
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Physical
measure definition
Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported.
time frame
3.2 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR boy patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: School

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0033
source section id
NCT01190930-om-0033
source outcome index
33
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: School
measure definition
Age standardized Quality of life, measured by the school subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported.
time frame
1.7 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Data are unavailable
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): School

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0034
source section id
NCT01190930-om-0034
source outcome index
34
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): School
measure definition
Age standardized Quality of life, measured by the school subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported.
time frame
2.4 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Data are unavailable
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: School

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0035
source section id
NCT01190930-om-0035
source outcome index
35
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: School
measure definition
Age standardized Quality of life, measured by the school subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported.
time frame
3.2 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Data are unavailable
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Social Functioning

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0036
source section id
NCT01190930-om-0036
source outcome index
36
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Social Functioning
measure definition
Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported.
time frame
1.7 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0037
source section id
NCT01190930-om-0037
source outcome index
37
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
measure definition
Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported.
time frame
2.4 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Unnamed quality-of-life measure · Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Social Functioning

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
qol key
qol-0038
source section id
NCT01190930-om-0038
source outcome index
38
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Social Functioning
measure definition
Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported.
time frame
3.2 Years
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
AR boy patients who had data collected
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric
nct id
NCT01190930
trial label
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
regulator-cited
discovery note
Found because this study's registry identifier is printed in an FDA approval notice, an FDA product label or an NCI summary held by this site. The citing document and the exact position of the identifier inside it are recorded. Being cited is not a statement that the study supports this treatment.
outcome Count
6
harms Count
10
qol Count
32
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0000
    source section id
    NCT01190930-om-0000
    source outcome index
    0
    endpoint
    Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization
    endpoint definition
    DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated.
    time origin
    5.7 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Average Risk (AR) B-ALL patients who were randomized and started maintenance
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0001
    source section id
    NCT01190930-om-0001
    source outcome index
    1
    endpoint
    DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization
    endpoint definition
    DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated.
    time origin
    5.7 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Average Risk (AR) B-ALL patients who were randomized and started maintenance
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0002
    source section id
    NCT01190930-om-0002
    source outcome index
    2
    endpoint
    DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens
    endpoint definition
    DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated.
    time origin
    5.1 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0003
    source section id
    NCT01190930-om-0003
    source outcome index
    3
    endpoint
    DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care
    endpoint definition
    DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated.
    time origin
    5.1 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0004
    source section id
    NCT01190930-om-0004
    source outcome index
    4
    endpoint
    Sample Collection of Central Path Review Slides in B-LLy Patients
    endpoint definition
    Percent of B-LLy patients who had adequate/usable samples of samples collected will be reported.
    time origin
    Up to 1 month
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    patients who had samples collected near diagnosis
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0005
    source section id
    NCT01190930-om-0005
    source outcome index
    5
    endpoint
    Event Free Survival (EFS) for B-LLy Patients
    endpoint definition
    EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated.
    time origin
    5 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Ineligible patients are excluded
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0000
    arm key
    OG000
    arm label
    B-ALL Average Risk: MTX 20 mg/m^2/Week Starting Dose
    regimen
    Cons. (4 wks): vincristine (VIN) day (d) 1; mercaptopurine (MP) d 1-28; IT MTX d 1/8/15; leucovorin (LV) d 3-4/10-11/17-18 Int. maint. I (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 31; LV d 33-34 Delayed-intensification (8 wks): dexamethasone (DEX) d 1-7/15-21; VIN and doxorubicin d 1/8/15; pegaspargase d 4; cyclophosphamide d 29; thioguanine d 29-42; cytarabine d 29-32/33-39; IT MTX d 1/29; LV d 3-4/31-32 Int. maint. II (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 1/31; LV d 3-4/33-34 Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1 Arm A: VIN d 1/29/57; DEX d 1-5/29-33/57-61; MTX weekly d 8-78; MP d 1-84; and IT MTX d 1 Arm B: VIN d 1/29/57; DEX d 1-5/29-33/57-61; high-dose (HD) MTX weekly d 8-78; MP d 1-84; and IT MTX d 1 Arm C: VIN d 1; DEX d 1-5; MTX weekly d 8-78; MP d 1-84; IT MTX d 1 Arm D: VIN d 1; DEX d 1-5; HD MTX weekly d 8-78; MP d 1-84; IT MTX d 1
    analyzed count
    1186
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01190930-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0000
    arm key
    OG001
    arm label
    B-ALL Average Risk: MTX 40 mg/m^2/Week Starting Dose
    regimen
    Cons. (4 wks): vincristine (VIN) day (d) 1; mercaptopurine (MP) d 1-28; IT MTX d 1/8/15; leucovorin (LV) d 3-4/10-11/17-18 Int. maint. I (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 31; LV d 33-34 Delayed-intensification (8 wks): dexamethasone (DEX) d 1-7/15-21; VIN and doxorubicin d 1/8/15; pegaspargase d 4; cyclophosphamide d 29; thioguanine d 29-42; cytarabine d 29-32/33-39; IT MTX d 1/29; LV d 3-4/31-32 Int. maint. II (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 1/31; LV d 3-4/33-34 Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1 Arm A: VIN d 1/29/57; DEX d 1-5/29-33/57-61; MTX weekly d 8-78; MP d 1-84; and IT MTX d 1 Arm B: VIN d 1/29/57; DEX d 1-5/29-33/57-61; high-dose (HD) MTX weekly d 8-78; MP d 1-84; and IT MTX d 1 Arm C: VIN d 1; DEX d 1-5; MTX weekly d 8-78; MP d 1-84; IT MTX d 1 Arm D: VIN d 1; DEX d 1-5; HD MTX weekly d 8-78; MP d 1-84; IT MTX d 1
    analyzed count
    1178
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01190930-om-0000#groups/OG001
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0001
    arm key
    OG000
    arm label
    B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks
    regimen
    Cons. (4 wks): vincristine (VIN) day (d) 1; mercaptopurine (MP) d 1-28; IT MTX d 1/8/15; leucovorin (LV) d 3-4/10-11/17-18 Int. maint. I (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 31; LV d 33-34 Delayed-intensification (8 wks): dexamethasone (DEX) d 1-7/15-21; VIN and doxorubicin d 1/8/15; pegaspargase d 4; cyclophosphamide d 29; thioguanine d 29-42; cytarabine d 29-32/33-39; IT MTX d 1/29; LV d 3-4/31-32 Int. maint. II (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 1/31; LV d 3-4/33-34 Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1 Arm A: VIN d 1/29/57; DEX d 1-5/29-33/57-61; MTX weekly d 8-78; MP d 1-84; and IT MTX d 1 Arm B: VIN d 1/29/57; DEX d 1-5/29-33/57-61; high-dose (HD) MTX weekly d 8-78; MP d 1-84; and IT MTX d 1 Arm C: VIN d 1; DEX d 1-5; MTX weekly d 8-78; MP d 1-84; IT MTX d 1 Arm D: VIN d 1; DEX d 1-5; HD MTX weekly d 8-78; MP d 1-84; IT MTX d 1
    analyzed count
    1186
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01190930-om-0001#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0001
    arm key
    OG001
    arm label
    B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks
    regimen
    Cons. (4 wks): vincristine (VIN) day (d) 1; mercaptopurine (MP) d 1-28; IT MTX d 1/8/15; leucovorin (LV) d 3-4/10-11/17-18 Int. maint. I (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 31; LV d 33-34 Delayed-intensification (8 wks): dexamethasone (DEX) d 1-7/15-21; VIN and doxorubicin d 1/8/15; pegaspargase d 4; cyclophosphamide d 29; thioguanine d 29-42; cytarabine d 29-32/33-39; IT MTX d 1/29; LV d 3-4/31-32 Int. maint. II (8 wks): VIN and MTX d 1/11/21/31/41; IT MTX d 1/31; LV d 3-4/33-34 Maintenance: repeat every 12 wks for 2 yrs (girls), 3 yrs (boys) from start IM1 Arm A: VIN d 1/29/57; DEX d 1-5/29-33/57-61; MTX weekly d 8-78; MP d 1-84; and IT MTX d 1 Arm B: VIN d 1/29/57; DEX d 1-5/29-33/57-61; high-dose (HD) MTX weekly d 8-78; MP d 1-84; and IT MTX d 1 Arm C: VIN d 1; DEX d 1-5; MTX weekly d 8-78; MP d 1-84; IT MTX d 1 Arm D: VIN d 1; DEX d 1-5; HD MTX weekly d 8-78; MP d 1-84; IT MTX d 1
    analyzed count
    1178
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01190930-om-0001#groups/OG001
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0002
    arm key
    OG000
    arm label
    B-ALL Low Risk Arm I (LR-M)
    regimen
    Consolidation (19 w): vincristine (VIN) day(d) 15/22/78/85; IV/IT methotrexate (MTX) d8/29/50/71/92/113; leucovorin (LV) d9-10/30-31/51-52/72-73/93-94/114-115; dexamethasone (DEX) d15-21/78-84; mercaptopurine (MP) d 1-133. Maint.: VIN d1/8; DEX d1-7; MTX\* PO wkly d1-106; MP d 1-112. Repeat every 16 w until 2.5 yrs from dx. IT MTX d1/85 (course 1\&4), d 57 (course 2\&5), d29 (course 3\&6). Course 7: VIN d1/8; DEX d 1-7; MTX PO wkly d8-64; and MP d1-70. \*Patients do not receive MTX PO on d w/ IT MTX.
    analyzed count
    301
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01190930-om-0002#groups/OG000
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0002
    arm key
    OG001
    arm label
    B-ALL Low Risk Arm II (LR-C)
    regimen
    Consolidation (4 w): VIN d1; MP d1-28; IT MTX d1/8/15 Interim Maint. I (8 w): VIN \& IV MTX d1/11/21/31/41; IT MTX d31 Delayed-intensification (8 w): DEX d1-7/15-21; VIN \& doxorubicin d1/8/15; pegaspargase d4; cyclophosphamide d29; thioguanine d 29-42; cytarabine d29-32/36-39; IT MTX d1/29 Interim Maint. II (8 w): VIN \& IV MTX d1/11/21/31/41; IT MTX d1/31 Maint.: VIN d1; DEX d1-5; MTX PO wkly d22-78; MP d 1-84; IT MTX d1. Rpt every 12 w for 2 yrs:girls, 3 yrs:boys from start IM1
    analyzed count
    302
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01190930-om-0002#groups/OG001
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Standard Risk With Down Syndrome
    regimen
    Consolidation (4 w): vincristine (VIN) d1; MP d1-28; IT methotrexate (MTX) d1/8/15; leucovorin (LV) d3-4/10-11/17-18 Interim maintenance I (8 wks): VIN \& IV MTX d1/11/21/31/41; IT MTX d31; LV d36-34 Delayed-intensification (8 wks): Patients receive dexamethasone (DEX) d1-7/15-21; VIN \& doxorubicin d1/8/15; pegaspargase d4; cyclophosphamide d29; thioguanine d 29-42; cytarabine d29-32/33-39; IT MTX d1/29; and LV d3-4/31-32 Interim maintenance II (8 wks): VIN \& IV MTX d1/11/21/31/41; IT MTX d1/31; and LV d3-4/33-34 Maintenance: VIN d1; DEX d1-5; PO MTX wkly d8-78; MP d1-84; and IT MTX d1. Courses repeat every 12 wks for 2 years (timed from the start of interim maintenance I therapy).
    analyzed count
    224
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01190930-om-0003#groups/OG000
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0004
    arm key
    OG000
    arm label
    B-LLy
    regimen
    Induction: same trt as B-ALL; Consolidation (4 wks): vincristine sulfate day 1; mercaptopurine days 1-28; IT methotrexate (MTX) days 1/8/15; leucovorin calcium days 3-4,10-11,17-18 Interim maintenance I (8 wks): vincristine sulfate and MTX 2-15 min days 1/11/21/31/41; IT MTX day 31; leucovorin calcium days 33-34 Delayed-intensification (8 wks): dexamethasone days 1-7 and 15-21; vincristine sulfate and doxorubicin hydrochloride on days 1/8/15; pegaspargase 1-2 hrs day 4; cyclophosphamide day 29; thioguanine days 29-42; cytarabine 29-32, 33-39; IT MTX days 1/29; and leucovorin calcium days 3-4, 31-32 Interim maintenance II (8 wks): vincristine sulfate and MTX days 1/11/21/31/41; IT MTX days 1/31; and leucovorin calcium days 3-4, 33/34 Maintenance: vincristine sulfate day 1; dexamethasone days 1-5; MTX weekly days 8-78; mercaptopurine days 1-84; and IT MTX day 1. Courses repeat every 4 wks for 2 yrs (from the start of IMI therapy).
    analyzed count
    39
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01190930-om-0004#groups/OG000
  9. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    outcome key
    om-0005
    arm key
    OG000
    arm label
    B-LLy
    regimen
    Induction: same trt as B-ALL; Consolidation (4 wks): vincristine sulfate day 1; mercaptopurine days 1-28; IT methotrexate (MTX) days 1/8/15; leucovorin calcium days 3-4,10-11,17-18 Interim maintenance I (8 wks): vincristine sulfate and MTX 2-15 min days 1/11/21/31/41; IT MTX day 31; leucovorin calcium days 33-34 Delayed-intensification (8 wks): dexamethasone days 1-7 and 15-21; vincristine sulfate and doxorubicin hydrochloride on days 1/8/15; pegaspargase 1-2 hrs day 4; cyclophosphamide day 29; thioguanine days 29-42; cytarabine 29-32, 33-39; IT MTX days 1/29; and leucovorin calcium days 3-4, 31-32 Interim maintenance II (8 wks): vincristine sulfate and MTX days 1/11/21/31/41; IT MTX days 1/31; and leucovorin calcium days 3-4, 33/34 Maintenance: vincristine sulfate day 1; dexamethasone days 1-5; MTX weekly days 8-78; mercaptopurine days 1-84; and IT MTX day 1. Courses repeat every 4 wks for 2 yrs (from the start of IMI therapy).
    analyzed count
    48
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01190930-om-0005#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    harm key
    EG000
    source section id
    NCT01190930-ae
    event group key
    EG000
    event group label
    B-ALL
    serious affected
    72
    serious at risk
    9229
    other affected
    1776
    other at risk
    9229
    frequency threshold
    0
    collection period
    Up to 9 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    harm key
    EG001
    source section id
    NCT01190930-ae
    event group key
    EG001
    event group label
    B-LLy
    serious affected
    0
    serious at risk
    48
    other affected
    30
    other at risk
    48
    frequency threshold
    0
    collection period
    Up to 9 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    harm key
    EG002
    source section id
    NCT01190930-ae
    event group key
    EG002
    event group label
    B-ALL Average Risk
    serious affected
    16
    serious at risk
    3122
    other affected
    1037
    other at risk
    3122
    frequency threshold
    0
    collection period
    Up to 9 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    harm key
    EG003
    source section id
    NCT01190930-ae
    event group key
    EG003
    event group label
    Standard Risk With Down Syndrome
    serious affected
    9
    serious at risk
    224
    other affected
    191
    other at risk
    224
    frequency threshold
    0
    collection period
    Up to 9 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    harm key
    EG004
    source section id
    NCT01190930-ae
    event group key
    EG004
    event group label
    B-ALL Low Risk Arm I (LR-M)
    serious affected
    0
    serious at risk
    301
    other affected
    103
    other at risk
    301
    frequency threshold
    0
    collection period
    Up to 9 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    harm key
    EG005
    source section id
    NCT01190930-ae
    event group key
    EG005
    event group label
    B-ALL Low Risk Arm II (LR-C)
    serious affected
    0
    serious at risk
    302
    other affected
    143
    other at risk
    302
    frequency threshold
    0
    collection period
    Up to 9 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    harm key
    EG006
    source section id
    NCT01190930-ae
    event group key
    EG006
    event group label
    B-ALL Average Risk-Arm A
    serious affected
    7
    serious at risk
    600
    other affected
    180
    other at risk
    600
    frequency threshold
    0
    collection period
    Up to 9 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    harm key
    EG007
    source section id
    NCT01190930-ae
    event group key
    EG007
    event group label
    B-ALL Average Risk-Arm B
    serious affected
    7
    serious at risk
    586
    other affected
    204
    other at risk
    586
    frequency threshold
    0
    collection period
    Up to 9 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  9. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    harm key
    EG008
    source section id
    NCT01190930-ae
    event group key
    EG008
    event group label
    B-ALL Average Risk-Arm C
    serious affected
    4
    serious at risk
    586
    other affected
    156
    other at risk
    586
    frequency threshold
    0
    collection period
    Up to 9 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  10. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    harm key
    EG009
    source section id
    NCT01190930-ae
    event group key
    EG009
    event group label
    B-ALL Average Risk-Arm D
    serious affected
    3
    serious at risk
    592
    other affected
    152
    other at risk
    592
    frequency threshold
    0
    collection period
    Up to 9 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0007
    source section id
    NCT01190930-om-0007
    source outcome index
    7
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional
    measure definition
    Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    2 Months
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    AR patients who had data collected
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0008
    source section id
    NCT01190930-om-0008
    source outcome index
    8
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional
    measure definition
    Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    1 year
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    AR patients who had data collected
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0009
    source section id
    NCT01190930-om-0009
    source outcome index
    9
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional
    measure definition
    Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    1.7 years
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    AR patients who had data collected
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0010
    source section id
    NCT01190930-om-0010
    source outcome index
    10
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
    measure definition
    Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    2.5 years
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    AR patients who had data collected
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0011
    source section id
    NCT01190930-om-0011
    source outcome index
    11
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional
    measure definition
    Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Genetic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    3.2 years
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    AR boy patients who had data collected
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0012
    source section id
    NCT01190930-om-0012
    source outcome index
    12
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical
    measure definition
    Age and gender standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    2 Months
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    AR patients who had data collected
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0013
    source section id
    NCT01190930-om-0013
    source outcome index
    13
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical
    measure definition
    Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    1 Year
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    AR patients who had data collected
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0014
    source section id
    NCT01190930-om-0014
    source outcome index
    14
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical
    measure definition
    Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    1.7 years
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    AR patients who had data collected
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  9. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0015
    source section id
    NCT01190930-om-0015
    source outcome index
    15
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
    measure definition
    Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    2.4 Years
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    AR patients who had data collected
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  10. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0016
    source section id
    NCT01190930-om-0016
    source outcome index
    16
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical
    measure definition
    Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    3.2 years
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    AR boy patients who had data collected
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  11. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0017
    source section id
    NCT01190930-om-0017
    source outcome index
    17
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: School
    measure definition
    Age standardized Quality of life, measured by the school subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    2 Months
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    Data are unavailable
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  12. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric
    nct id
    NCT01190930
    qol key
    qol-0018
    source section id
    NCT01190930-om-0018
    source outcome index
    18
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: School
    measure definition
    Age standardized Quality of life, measured by the school subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported.
    time frame
    1 Year
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    Data are unavailable
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
setting source links

    Preserved source evidence · Not medical advice